symbol,synonyms,gene_locus,gene_id,transcript_id,conservation,conservation_ortholog,conservation_species,biological_context,context_detail,tissue/cell line,genome_variation,variation_detail,epigenetic_modification,modification_detail,expression,expression_detail,regulator_type,regulator,regulator_interaction,regulator_effect,target_type,target,target_interaction,target_effect,experimental_method,molecular_function,biological_process,pathway,functional_mechanism,clinical_detail,drug,description,pmid
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,hypertension,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Genotyping,NA,NA,NA,NA,NA,NA,Polymorphisms in the long non-codingrna cdkn2b-as1 may contribute to higher systolic blood pressure levels in hypertensive patients.,26944720
EMX2OS,NCRNA00045;EMX2-AS1,10q26.11,HSALNG0080912,"HSALNT0168642,HSALNT0168643,HSALNT0168644,HSALNT0168645,HSALNT0168654,HSALNT0168655,HSALNT0168656,HSALNT0168657,HSALNT0168659,HSALNT0288942,HSALNT0360165,HSALNT0360166,HSALNT0360167,HSALNT0360168,HSALNT0360169,HSALNT0360170,HSALNT0360171,HSALNT0360172,HSALNT0360173",,NA,,Disease,hypertension,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Q-RCR;Wetern blotting assay,NA,NA,NA,NA,NA,NA,Notoginsenoside r1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding rna ak094457.,26045775
GAS5,SNHG2;NCRNA00030,1q25.1,HSALNG0008545,"HSALNT0017659,HSALNT0017660,HSALNT0017661,HSALNT0017663,HSALNT0017666,HSALNT0017667,HSALNT0017670,HSALNT0017671,HSALNT0017679,HSALNT0017696,HSALNT0017697,HSALNT0017700,HSALNT0017701,HSALNT0017702,HSALNT0017703,HSALNT0017704,HSALNT0017705,HSALNT0017706,HSALNT0017716,HSALNT0017717,HSALNT0017719,HSALNT0017720,HSALNT0017721,HSALNT0017722,HSALNT0017723,HSALNT0017724,HSALNT0017725,HSALNT0017726,HSALNT0017728,HSALNT0017732,HSALNT0017737,HSALNT0017738,HSALNT0017739,HSALNT0017740,HSALNT0017744,HSALNT0017748,HSALNT0017749,HSALNT0017751,HSALNT0017753,HSALNT0017757,HSALNT0017760,HSALNT0017768,HSALNT0017773,HSALNT0017776,HSALNT0017777,HSALNT0296610,HSALNT0296611,HSALNT0296612,HSALNT0296613,HSALNT0296614,HSALNT0296615,HSALNT0296616,HSALNT0296617,HSALNT0296619,HSALNT0296620,HSALNT0296621,HSALNT0296622,HSALNT0296623,HSALNT0296624,HSALNT0296625,HSALNT0296626,HSALNT0296627,HSALNT0296628,HSALNT0296629,HSALNT0296630,HSALNT0296631,HSALNT0296632,HSALNT0296633,HSALNT0296634,HSALNT0296635,HSALNT0296636,HSALNT0296637,HSALNT0296638,HSALNT0296639,HSALNT0296640,HSALNT0296641,HSALNT0296642,HSALNT0296643,HSALNT0296644,HSALNT0296645,HSALNT0296646",,NA,,Disease,hypertension,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Ish,NA,NA,NA,NA,NA,NA,This study identifiedgas5 as a critical regulator in hypertension and demonstrated the potential of gene therapy and drug development for treating hypertension.,27432865
LINC01227,,16q23.2,HSALNG0112932,"HSALNT0234057,HSALNT0234058,HSALNT0234059,HSALNT0234060,HSALNT0234061,HSALNT0234062,HSALNT0234063,HSALNT0234064,HSALNT0234065,HSALNT0234066,HSALNT0234067,HSALNT0234068,HSALNT0234069,HSALNT0234070,HSALNT0234071,HSALNT0234072,HSALNT0234073,HSALNT0234074,HSALNT0234075,HSALNT0234076,HSALNT0234077,HSALNT0234078,HSALNT0234079,HSALNT0234080,HSALNT0234081,HSALNT0234082,HSALNT0234083,HSALNT0234084,HSALNT0234085,HSALNT0234086,HSALNT0234087,HSALNT0234088,HSALNT0234089,HSALNT0234097,HSALNT0234106,HSALNT0234107,HSALNT0234108,HSALNT0234111,HSALNT0234112,HSALNT0234113,HSALNT0234114,HSALNT0234115,HSALNT0234116,HSALNT0234117,HSALNT0234119,HSALNT0234120,HSALNT0234121,HSALNT0234124,HSALNT0234126,HSALNT0234128,HSALNT0234129,HSALNT0234131,HSALNT0234133,HSALNT0234134,HSALNT0234138,HSALNT0234140,HSALNT0234142,HSALNT0234144,HSALNT0234146,HSALNT0234147,HSALNT0234149,HSALNT0387172,HSALNT0387173,HSALNT0387174,HSALNT0387175,HSALNT0387176,HSALNT0387177,HSALNT0387178,HSALNT0387180,HSALNT0387181,HSALNT0387182,HSALNT0387183,HSALNT0387184,HSALNT0387185,HSALNT0387186,HSALNT0387187,HSALNT0387188,HSALNT0387189,HSALNT0387192,HSALNT0387193,HSALNT0387194,HSALNT0387195,HSALNT0387196,HSALNT0387197,HSALNT0387198,HSALNT0387199,HSALNT0387200,HSALNT0387201,HSALNT0387202,HSALNT0387203,HSALNT0387204,HSALNT0387205,HSALNT0387206,HSALNT0387207,HSALNT0387208,HSALNT0387209",,NA,,Disease,hypertension,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR,NA,NA,NA,NA,NA,NA,"By comparing the circulating lncRNAs expression profiles between hypertensive patients and healthy controls,we identified a lncRNA-ak098656,strongly upregulated in the plasma of hypertensive patients,and predominantly expressed in vsmcs.Ak098656 promoted vsmcs synthetic phenotype evidenced by increasing vsmc proliferation and migration,elevating extracellular matrix proteins,whereas lowering contractile proteins.Furthermore,ak098656 was demonstrated to directly bind with the vsmcs-specific contractile protein,myosin heavy chain-11,and an essential component of extracellular matrix,fibronectin-1,and finally lowered these protein levels through protein degradation.Ak098656 was also shown to bind with 26s proteasome non-atpase regulatory subunit 11 and facilitated myosin heavy chain-11 to interact with this protein.In vivo,ak098656 transgenic rats showed spontaneous development of hypertension,with elevated vsmcs synthetic phenotype and narrowed resistant arteries.Transgenic rats also showed slight cardiac hypertrophy without other complications,which was similar with early pathophysiological changes of hypertension.",29279317
